RAPT Therapeutics, Inc. financial data

Symbol
RAPT on Nasdaq
Industry
Pharmaceutical Preparations
Location
561 Eccles Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
FLX Bio, Inc. (to 1/2/2019)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 776 % -43.4%
Debt-to-equity 17.2 % +62.8%
Return On Equity -86 % -86.2%
Return On Assets -73.4 % -75.6%
Operating Margin -5.62K % -210%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.9M shares +1.59%
Common Stock, Shares, Outstanding 34.4M shares +0.42%
Entity Public Float 399M USD +25.1%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.9M shares +1.4%
Weighted Average Number of Shares Outstanding, Diluted 38.9M shares +1.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 101M USD +21.5%
General and Administrative Expense 27.8M USD +22%
Operating Income (Loss) -129M USD -21.6%
Nonoperating Income (Expense) 8.55M USD +17.2%
Net Income (Loss) Attributable to Parent -120M USD -22%
Earnings Per Share, Basic -3.13 USD/shares -16.4%
Earnings Per Share, Diluted -3.13 USD/shares -16.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.1M USD -26.1%
Marketable Securities, Current 77.8M USD -49.8%
Cash, Cash Equivalents, and Short-term Investments 115M USD
Assets, Current 120M USD -41.9%
Property, Plant and Equipment, Net 1.93M USD -34.8%
Operating Lease, Right-of-Use Asset 4.3M USD -29.5%
Other Assets, Noncurrent 447K USD -89.5%
Assets 127M USD -42.4%
Accounts Payable, Current 2.72M USD +0.97%
Accrued Liabilities, Current 9.49M USD -7.85%
Liabilities, Current 14.8M USD -3.98%
Operating Lease, Liability, Noncurrent 3.16M USD -44.2%
Liabilities 18M USD -14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -47K USD +73.9%
Retained Earnings (Accumulated Deficit) -543M USD -28.5%
Stockholders' Equity Attributable to Parent 109M USD -45.3%
Liabilities and Equity 127M USD -42.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.1M USD -45.6%
Net Cash Provided by (Used in) Financing Activities 9.04M USD +7690%
Net Cash Provided by (Used in) Investing Activities 15.9M USD -37.2%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 34.4M shares +0.42%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.16M USD -132%
Deferred Tax Assets, Valuation Allowance 107M USD +32.6%
Deferred Tax Assets, Gross 108M USD +31.6%
Operating Lease, Liability 6.91M USD -23.2%
Payments to Acquire Property, Plant, and Equipment 105K USD -86.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -120M USD -22.5%
Lessee, Operating Lease, Liability, to be Paid 7.65M USD -26.1%
Property, Plant and Equipment, Gross 11.5M USD -1.66%
Operating Lease, Liability, Current 2.57M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.66M USD -6.76%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.86M USD +5.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 748K USD -45.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.14M USD -19.7%
Deferred Tax Assets, Operating Loss Carryforwards 58.2M USD +10.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 4.67M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.14M USD -5.4%
Operating Lease, Payments 600K USD +20%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 19.5M USD +37.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%